Regarding Combined Pediatric and Adult Trials Submitted to the US Food and Drug Administration 2012-2018
| Autor: | J. Robert Powell, Jack Cook, Daniel E. Weiner |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
medicine.medical_specialty Prescription Drugs Time Factors Adolescent Orphan Drug Production MEDLINE Risk Assessment Article Food and drug administration Drug approval Medicine Humans Pharmacology (medical) Intensive care medicine Letters to the Editor Child Letter to the Editor Drug Approval Drug Labeling Pharmacology Biological Products Clinical Trials as Topic business.industry United States Food and Drug Administration Patient Selection Age Factors United States Patient Safety business Perspectives |
| Zdroj: | Clin Pharmacol Ther Clinical Pharmacology and Therapeutics |
| ISSN: | 1532-6535 |
| Popis: | Despite legislation incentivizing and requiring drug companies to conduct pediatric clinical trials, there still is a 9-year delay in drug approval for pediatric labeling after the initial adult drug approval. The aim of this study was to review the experience of the US Food and Drug Administration (FDA) with combined pediatric and adult trials as a means for expediting pediatric approval and labeling. Combined pediatric and adult trials submitted to the FDA from 2012 to 2018 were reviewed. Only the publicly available labels and reviews were utilized for this analysis. Combined trials were identified for 72 products, with a total of 156 combined adult and pediatric trials. The therapeutic areas with the largest number of combined trials were in pulmonology for products reviewed under the Best Pharmaceuticals for Children Act (BPCA) and/or the Pediatric Research Equity Act (PREA), and hematology reviewed under the Orphan Drug Act (ODA). All drugs that utilized combined pediatric and adult clinical trials were approved simultaneously for both the adults and that part of the pediatric population. A separate pediatric subgroup efficacy analysis was reported in 57% and 48% of products under BPCA/PREA and the ODA, respectively, with a separate safety analysis in 48% and 38% of these products. When considering both BPCA/PREA and orphan drug studies, all the combined pediatric and adult trials allowed concurrent approval and labeling for part of the pediatric population at the time of the adult approval. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text